Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing the Potential Risk of Heart Failure

A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released by the U.S. FDA stating that saxagliptin and alogliptin might increase the risk of heart failure, in particular in patients who have other risk factors for heart failure. The product safety information in the U.S. and Canada were recently updated to include this risk.

Data and Resources

Additional Info

Field	Value
Last Updated	April 17, 2026, 21:25 (UTC)
Created	April 17, 2026, 21:25 (UTC)
criticality_level	[]
geographic_scope	[]
open_canada_collection	publication
open_canada_date_published	2017-06-15 00:00:00
open_canada_keywords	{"fr": ["Résumé de l'examen de l'innocuité", "Dipeptidylpeptidase-4", "DPP-4", "inhibiteurs", "évaluation", "risque", "insuffisance cardiaque", "saxagliptine", "alogliptine", "autres facteurs de risque"], "en": ["Summary Safety Review", "Dipeptidylpeptidase-4", "DPP-4", "Inhibitors", "assessing", "risk", "heart failure", "saxagliptin", "alogliptin", "other risk factors"]}
open_canada_subject	["health_and_safety"]
sensitivity_level	unrestricted
title_fr	Résumé de l’examen de l’innocuité - Inhibiteurs de la dipeptidylpeptidase-4 (DPP-4) - Évaluation du risque potentiel d’insuffisance cardiaque
update_frequency	as_needed